



## Adenosine Metabolism-Key Targets in Cardiovascular Pharmacology

Guest Editor:

**Dr. Barbara Kutryb-Zając**

Department of Biochemistry,  
Medical University of Gdansk, 80-  
211 Gdansk, Poland

Deadline for manuscript  
submissions:

**closed (25 September 2023)**

### Message from the Guest Editor

Pharmacological modulations of adenosine signaling may be recognized as a valuable therapeutic approach for many cardiovascular pathologies, including atherosclerosis, myocardial ischemia-reperfusion injury, hypertension, thrombosis, and diabetes. This Special Issue will explore in depth the role of adenosine metabolism pathways and their association with cardiovascular diseases. Potential topics include, but are not limited to, the following:

- Intracellular and extracellular adenosine metabolism pathways;
- Targeting adenosine-mediated actions at cellular levels;
- Adenosine as a treatment for myocardial preservation;
- Inhibitors and activators of adenosine metabolism enzymes;
- Molecular biology of adenosine signaling;
- Bioinformatics of adenosine receptors;
- Adenosine metabolism in atherosclerosis;
- Adenosine metabolism in endothelial dysfunction;
- Adenosine metabolism in inflammation and cholesterol homeostasis;
- Anti-platelet effects of adenosine-regulated pathways;
- Adenosine-deaminase-anchoring proteins;
- Adenosine-converting enzymes as ideal physiologic biomarkers;
- Deficiency of adenosine deaminase 2;
- Nucleoside transporter and mitochondrial





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)